{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:13:20Z","timestamp":1770743600129,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.nucmedbio.2024.108963","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:56:35Z","timestamp":1728089795000},"page":"108963","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Influence of PEGylation on HER2-targeting retro A9 peptide analogue"],"prefix":"10.1016","volume":"138-139","author":[{"given":"Sushree Arpitabala","family":"Yadav","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. Kusum","family":"Vats","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drishty","family":"Satpati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2024.108963_bb0005","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10555-016-9649-6","article-title":"The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer","volume":"35","author":"Hsu","year":"2016","journal-title":"Cancer Metastasis Rev"},{"issue":"21","key":"10.1016\/j.nucmedbio.2024.108963_bb0010","doi-asserted-by":"crossref","first-page":"6482","DOI":"10.3390\/molecules26216482","article-title":"Radionuclide molecular imaging targeting HER2 in breast cancer with a focus on molecular probes into clinical trials and small peptides","volume":"26","author":"Ge","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000055396","article-title":"Biology of HER2 and its importance in breast cancer","volume":"61","author":"Yarden","year":"2001","journal-title":"Oncology"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1536012117745386","article-title":"Targeting HER2 in nuclear medicine for imaging and therapy","volume":"17","author":"Massicano","year":"2018","journal-title":"Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/1568011013354877","article-title":"Peptides as carrier for tumor diagnosis and treatment","volume":"1","author":"Langer","year":"2001","journal-title":"Anti Cancer Agents Med Chem"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","article-title":"Peptide receptors as molecular targets for cancer diagnosis and therapy","volume":"24","author":"Reubi","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0035","doi-asserted-by":"crossref","DOI":"10.7150\/thno.4024","article-title":"Radiolabeled peptides: valuable tools for the detection and treatment of cancer","volume":"2","author":"Fani","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0040","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1158\/1078-0432.CCR-07-0160","article-title":"Evaluation of an 111In-radiolabeled peptide as a targeting and imaging agent for ErbB-2 receptor\u2013expressing breast carcinomas","volume":"13","author":"Kumar","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0045","first-page":"693","article-title":"In vitro and in vivo evaluation of 64Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas","volume":"25","author":"Kumar","year":"2010","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0050","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2967\/jnumed.116.183863","article-title":"SPECT\/CT imaging of the novel HER2-targeted peptide probe 99mTc-HYNIC-H6F in breast cancer mouse models","volume":"58","author":"Li","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0055","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1515\/ract-2017-2868","article-title":"99mTc-HYNIC-(Ser)3-LTVPWY peptide bearing tricine as co-ligand for targeting and imaging of HER2 overexpression tumor","volume":"106","author":"Aligholikhamseh","year":"2018","journal-title":"Radiochim Acta"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0060","doi-asserted-by":"crossref","first-page":"15333","DOI":"10.1021\/acs.jmedchem.0c01340","article-title":"Peptide ligands specifically targeting HER2 receptor and the role played by a synthetic model system of the receptor extracellular domain: hypothesized future perspectives","volume":"63","author":"Luca","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0065","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1021\/acs.bioconjchem.3c00265","article-title":"Synthesis and 177Lu-labeling of first retro analog of HER2-targeting A9 peptide","volume":"34","author":"Sharma","year":"2023","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0070","doi-asserted-by":"crossref","first-page":"15720","DOI":"10.1038\/s41598-022-19201-9","article-title":"Synthesis and comparative evaluation of 177Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes","volume":"12","author":"Sharma","year":"2022","journal-title":"Scientific Reports-Nature"},{"issue":"4","key":"10.1016\/j.nucmedbio.2024.108963_bb0075","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jps.2600830432","article-title":"Distribution and tissue uptake of poly (ethylene glycol) with different molecular weights after intravenous administration to mice","volume":"83","author":"Yamaoka","year":"1994","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.nucmedbio.2024.108963_bb0080","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.nucmedbio.2024.108963_bb0085","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s11095-005-5278-4","article-title":"PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative","volume":"22","author":"Ramon","year":"2005","journal-title":"Pharm Res"},{"issue":"6","key":"10.1016\/j.nucmedbio.2024.108963_bb0090","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s11307-017-1072-z","article-title":"Preliminary PET\/CT imaging with somatostatin analogues 68Ga-DOTAGA-TATE and 68Ga-DOTAGA-TOC","volume":"19","author":"Satpati","year":"2017","journal-title":"Mol Imaging Biol"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108750","article-title":"Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment","volume":"113","author":"AlQahtani","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"10.1016\/j.nucmedbio.2024.108963_bb0100","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1002\/jps.21278","article-title":"The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics","volume":"97","author":"Fishburn","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.nucmedbio.2024.108963_bb0105","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.bioconjchem.0c00334","article-title":"Developing PEGylated reversed D-peptide as a novel HER2-targeted SPECT imaging probe for breast Cancer detection","volume":"31","author":"Du","year":"2020","journal-title":"Bioconjug Chem"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805124000891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T03:48:05Z","timestamp":1734666485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805124000891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":21,"alternative-id":["S0969805124000891"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108963","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of PEGylation on HER2-targeting retro A9 peptide analogue","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2024.108963","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108963"}}